CONTEXT: Thyroid status affects several aspects of cardiovascular risk profile, including lipid levels and blood pressure. Whether thyroid status affects the risk of coronary heart disease (CHD) and all-cause mortality remains controversial. DESIGN: The EPIC-Norfolk prospective population study. Mean follow-up was 10.6 years. PATIENTS: Study participants were 11 554 men and women aged 45-79 years, who were living in Norfolk, UK. MEASUREMENTS: Baseline cardiovascular risk factors were recorded and concentrations of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) were measured in baseline samples. Regression analyses were performed to assess the association between thyroid hormone levels and cardiovascular risk factors. A proportional hazards model was used to estimate the risk of CHD and all-cause mortality by baseline thyroid status. No information was available on thyroid treatment during follow-up. RESULTS: Thyroid abnormalities were common, particularly among women. Thyroid abnormalities were associated with an altered cardiovascular risk profile. Even within the normal range, thyroid hormone levels, TSH more strongly than FT4, were associated with lipid levels and blood pressure among both men and women. We did not observe a significant association between subclinical thyroid abnormalities and risk of CHD or all-cause mortality. CONCLUSIONS: Despite the association between thyroid hormone levels and cardiovascular risk factors, thyroid status was not statistically significantly associated with the risk of future CHD or all-cause mortality in this large cohort.
CONTEXT: Thyroid status affects several aspects of cardiovascular risk profile, including lipid levels and blood pressure. Whether thyroid status affects the risk of coronary heart disease (CHD) and all-cause mortality remains controversial. DESIGN: The EPIC-Norfolk prospective population study. Mean follow-up was 10.6 years. PATIENTS: Study participants were 11 554 men and women aged 45-79 years, who were living in Norfolk, UK. MEASUREMENTS: Baseline cardiovascular risk factors were recorded and concentrations of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) were measured in baseline samples. Regression analyses were performed to assess the association between thyroid hormone levels and cardiovascular risk factors. A proportional hazards model was used to estimate the risk of CHD and all-cause mortality by baseline thyroid status. No information was available on thyroid treatment during follow-up. RESULTS:Thyroid abnormalities were common, particularly among women. Thyroid abnormalities were associated with an altered cardiovascular risk profile. Even within the normal range, thyroid hormone levels, TSH more strongly than FT4, were associated with lipid levels and blood pressure among both men and women. We did not observe a significant association between subclinical thyroid abnormalities and risk of CHD or all-cause mortality. CONCLUSIONS: Despite the association between thyroid hormone levels and cardiovascular risk factors, thyroid status was not statistically significantly associated with the risk of future CHD or all-cause mortality in this large cohort.
Authors: Érique José F Peixoto de Miranda; Márcio Sommer Bittencourt; Alessandra C Goulart; Itamar S Santos; Silvia Maria de Oliveira Titan; Roberto Marini Ladeira; Sandhi Maria Barreto; Paulo A Lotufo; Isabela Judith Martins Benseñor Journal: Clin Exp Nephrol Date: 2017-03-27 Impact factor: 2.801
Authors: Carole E Aubert; Carmen Floriani; Douglas C Bauer; Bruno R da Costa; Daniel Segna; Manuel R Blum; Tinh-Hai Collet; Howard A Fink; Anne R Cappola; Lamprini Syrogiannouli; Robin P Peeters; Bjørn O Åsvold; Wendy P J den Elzen; Robert N Luben; Alexandra P Bremner; Apostolos Gogakos; Richard Eastell; Patricia M Kearney; Mari Hoff; Erin Le Blanc; Graziano Ceresini; Fernando Rivadeneira; André G Uitterlinden; Kay-Tee Khaw; Arnulf Langhammer; David J Stott; Rudi G J Westendorp; Luigi Ferrucci; Graham R Williams; Jacobijn Gussekloo; John P Walsh; Drahomir Aujesky; Nicolas Rodondi Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Bjørn O Åsvold; Lars J Vatten; Trine Bjøro; Douglas C Bauer; Alexandra Bremner; Anne R Cappola; Graziano Ceresini; Wendy P J den Elzen; Luigi Ferrucci; Oscar H Franco; Jayne A Franklyn; Jacobijn Gussekloo; Giorgio Iervasi; Misa Imaizumi; Patricia M Kearney; Kay-Tee Khaw; Rui M B Maciel; Anne B Newman; Robin P Peeters; Bruce M Psaty; Salman Razvi; José A Sgarbi; David J Stott; Stella Trompet; Mark P J Vanderpump; Henry Völzke; John P Walsh; Rudi G J Westendorp; Nicolas Rodondi Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: Vicky A LeGrys; Michele Jonsson Funk; Carol E Lorenz; Ayush Giri; Rebecca D Jackson; JoAnn E Manson; Robin Schectman; Todd L Edwards; Gerardo Heiss; Katherine E Hartmann Journal: J Clin Endocrinol Metab Date: 2013-03-28 Impact factor: 5.958
Authors: Layal Chaker; Christine Baumgartner; Wendy P J den Elzen; Tinh-Hai Collet; M Arfan Ikram; Manuel R Blum; Abbas Dehghan; Christiane Drechsler; Robert N Luben; Marileen L P Portegies; Giorgio Iervasi; Marco Medici; David J Stott; Robin P Dullaart; Ian Ford; Alexandra Bremner; Anne B Newman; Christoph Wanner; José A Sgarbi; Marcus Dörr; W T Longstreth; Bruce M Psaty; Luigi Ferrucci; Rui M B Maciel; Rudi G Westendorp; J Wouter Jukema; Graziano Ceresini; Misa Imaizumi; Albert Hofman; Stephan J L Bakker; Jayne A Franklyn; Kay-Tee Khaw; Douglas C Bauer; John P Walsh; Salman Razvi; Jacobijn Gussekloo; Henry Völzke; Oscar H Franco; Anne R Cappola; Nicolas Rodondi; Robin P Peeters Journal: J Clin Endocrinol Metab Date: 2016-09-07 Impact factor: 5.958